{"id":"standard-chop","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-60%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of these drugs works synergistically to induce apoptosis in cancer cells, with cyclophosphamide and doxorubicin causing DNA damage, vincristine inhibiting microtubule formation, and prednisone suppressing the immune system's response to the cancer.","oneSentence":"Standard CHOP is a chemotherapy regimen that combines cyclophosphamide, doxorubicin, vincristine, and prednisone to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:13.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"},{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT07476105","phase":"NA","title":"Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B","enrollment":170},{"nctId":"NCT07123961","phase":"PHASE2","title":"Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-11-07","conditions":"Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation","enrollment":160},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT06846463","phase":"PHASE2","title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-05-27","conditions":"Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":21},{"nctId":"NCT07335120","phase":"","title":"A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma","status":"RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2024-10-30","conditions":"DLBCL","enrollment":800},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT03473249","phase":"PHASE4","title":"Effectiveness of Contrast-Enhanced Ultrasound","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-05-09","conditions":"Abdominal Injuries, Physical Abuse, Accidental Fall","enrollment":120},{"nctId":"NCT04696692","phase":"NA","title":"Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2021-02-09","conditions":"Diffuse Large B-cell Lymphoma","enrollment":60},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT05455697","phase":"PHASE1, PHASE2","title":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-01-26","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma","enrollment":35},{"nctId":"NCT07262099","phase":"NA","title":"Study of Effects of Dao-yin Exercise on the Patients With Breast Cancer Post Operation and Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-01-13","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT07026630","phase":"NA","title":"Activities of Daily Living (ADL) Virtual Reality (VR) for Acquired Brain Injury (ABI) Upper-Limb Rehabilitation","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2025-11","conditions":"Upper Limb Rehabilitation, Stroke","enrollment":""},{"nctId":"NCT04164472","phase":"NA","title":"NIH R01 Friend to Friend With Coaching","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-11-12","conditions":"Aggression","enrollment":5250},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT07011459","phase":"NA","title":"The Cooking for Health Optimization and Disease Prevention (CHOP) Trial","status":"RECRUITING","sponsor":"Tulane University","startDate":"2025-07-07","conditions":"Cardiovascular Diseases","enrollment":96},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT04546620","phase":"PHASE2","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2021-10-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":453},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT07057765","phase":"","title":"Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-05-05","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, Markers of Inflammation","enrollment":40},{"nctId":"NCT01359592","phase":"PHASE2","title":"S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-09","conditions":"Lymphoma","enrollment":159},{"nctId":"NCT02964858","phase":"NA","title":"Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2016-11","conditions":"NonHodgkin Lymphoma","enrollment":840},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT04566887","phase":"PHASE2","title":"Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-01","conditions":"Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT04720456","phase":"PHASE2","title":"SHAPE of Portal Hypertension in Children","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-11-03","conditions":"Hypertension, Portal","enrollment":120},{"nctId":"NCT04517435","phase":"PHASE1, PHASE2","title":"ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Deepa Jagadeesh","startDate":"2021-04-28","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":13},{"nctId":"NCT03263026","phase":"PHASE3","title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2018-03-20","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":256},{"nctId":"NCT03467373","phase":"PHASE1","title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-13","conditions":"B-Cell Lymphoma, Non-Hodgkin Lymphoma","enrollment":111},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT06750991","phase":"PHASE2","title":"CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"DLBCL","enrollment":34},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT06701344","phase":"PHASE2","title":"Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-04","conditions":"Enteropathy Associated T Cell Lymphoma","enrollment":7},{"nctId":"NCT02406092","phase":"PHASE3","title":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-13","conditions":"Non-Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT04745832","phase":"PHASE3","title":"Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)","status":"TERMINATED","sponsor":"MEI Pharma, Inc.","startDate":"2021-08-13","conditions":"Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma","enrollment":82},{"nctId":"NCT06573645","phase":"PHASE3","title":"A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Xia Yi","startDate":"2024-08-23","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":428},{"nctId":"NCT06569485","phase":"PHASE2","title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-23","conditions":"DLBCL","enrollment":38},{"nctId":"NCT00991211","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-01","conditions":"Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas","enrollment":549},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT05048732","phase":"EARLY_PHASE1","title":"Imaging Apoptosis for Lymphoma Treatment Response","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-12-06","conditions":"Diffuse Large B Cell Lymphoma","enrollment":12},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT05796271","phase":"PHASE1","title":"Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03458546","phase":"PHASE1","title":"Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-21","conditions":"Lymphoma, B-Cell","enrollment":14},{"nctId":"NCT05078840","phase":"","title":"PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors","status":"UNKNOWN","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-06-01","conditions":"Lymphoma, Non-Hodgkin's, Adult","enrollment":75},{"nctId":"NCT05675813","phase":"PHASE1, PHASE2","title":"Genotype-guided Treatment in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-13","conditions":"Peripheral T Cell Lymphoma","enrollment":264},{"nctId":"NCT04660799","phase":"PHASE2","title":"A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-24","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":50},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330},{"nctId":"NCT06015464","phase":"","title":"An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-09-01","conditions":"Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type","enrollment":81},{"nctId":"NCT03334942","phase":"NA","title":"Addressing Traumatic Stress Symptoms in Children","status":"UNKNOWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2017-11-02","conditions":"Violence, Non-accidental, Posttraumatic Stress Disorder, Parent-Child Relations","enrollment":132},{"nctId":"NCT05376709","phase":"NA","title":"A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-09-01","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT05934097","phase":"PHASE1","title":"FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fate Therapeutics","startDate":"2022-12","conditions":"Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma","enrollment":""},{"nctId":"NCT05886283","phase":"NA","title":"Qualitative and Quantitative Endothelium Changes After Cataract Surgery: Ultrasound Phacoemulsification vs Nanolaser Technique","status":"COMPLETED","sponsor":"University Tunis El Manar","startDate":"2017-03-01","conditions":"Effect of Cataract Surgery on Corneal Endothelium; About 2 Techniques","enrollment":74},{"nctId":"NCT00129090","phase":"PHASE3","title":"Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2003-03","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":450},{"nctId":"NCT05874778","phase":"PHASE2","title":"A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-15","conditions":"Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy","enrollment":108},{"nctId":"NCT05351346","phase":"PHASE3","title":"Genotype-guided Treatment in DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":1100},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT01796002","phase":"PHASE3","title":"Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-01","conditions":"Peripheral T-cell Lymphoma","enrollment":421},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT03200015","phase":"PHASE2","title":"Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2017-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT02531308","phase":"PHASE2","title":"Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2015-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":5},{"nctId":"NCT04442412","phase":"PHASE3","title":"Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-03-23","conditions":"Diffuse Large B-Cell Lymphoma, Elderly Patients","enrollment":430},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":"Follicular Non-Hodgkin's Lymphoma","enrollment":807},{"nctId":"NCT03853044","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-12-29","conditions":"Angioimmunoblastic T-cell Lymphoma","enrollment":23},{"nctId":"NCT04974996","phase":"PHASE1","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)","status":"WITHDRAWN","sponsor":"ADC Therapeutics S.A.","startDate":"2022-02-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT05280626","phase":"PHASE2","title":"First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-03-25","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":100},{"nctId":"NCT05238064","phase":"PHASE1, PHASE2","title":"Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-03","conditions":"PI3Kδ Inhibitor, Parsaclisib, CHOP","enrollment":30},{"nctId":"NCT05225597","phase":"NA","title":"The Effect of Intracameral Carbachol and Epinephrine on Choroidal Thickness","status":"COMPLETED","sponsor":"Ordu University","startDate":"2021-01-01","conditions":"Epinephrine Toxicity, Cataract, Carbachol Adverse Reaction","enrollment":81},{"nctId":"NCT01777152","phase":"PHASE3","title":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2013-01-31","conditions":"Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma","enrollment":452},{"nctId":"NCT00599170","phase":"PHASE2","title":"Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2008-01-10","conditions":"Diffuse, Large B-Cell, Lymphoma","enrollment":52},{"nctId":"NCT05040906","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2020-10-13","conditions":"Recruiting","enrollment":416},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT01410630","phase":"","title":"FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-09-07","conditions":"Lymphoma, Lymphoma, Non-Hodgkin, Large B Cell Diffuse Lymphoma","enrollment":66},{"nctId":"NCT03023878","phase":"PHASE2","title":"Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-13","conditions":"High-risk Diffuse Large B-Cell Lymphoma","enrollment":47},{"nctId":"NCT04544059","phase":"PHASE2","title":"Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":87},{"nctId":"NCT01889069","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-31","conditions":"Lymphoma","enrollment":159},{"nctId":"NCT00290498","phase":"PHASE2","title":"Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08-01","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT01881386","phase":"","title":"Lactate Imaging as a Tumour Biomarker","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2013-09-01","conditions":"Cancer","enrollment":37},{"nctId":"NCT00544219","phase":"NA","title":"PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2007-09","conditions":"Lymphoma","enrollment":156},{"nctId":"NCT01287741","phase":"PHASE3","title":"A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-26","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1418},{"nctId":"NCT00530179","phase":"NA","title":"FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2007-07","conditions":"Diffuse Large B Cell Lymphoma","enrollment":69},{"nctId":"NCT03800589","phase":"NA","title":"Assessment of Effectiveness Ex-Press Surgery Modification","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2010-12-01","conditions":"Glaucoma, Open-Angle, Glaucoma Secondary, Glaucoma, Primary Open Angle","enrollment":186},{"nctId":"NCT00151320","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":76},{"nctId":"NCT01414855","phase":"PHASE2","title":"A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-08-31","conditions":"Lymphoma, B-Cell","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":159,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard CHOP","genericName":"Standard CHOP","companyName":"Japan Clinical Oncology Group","companyId":"japan-clinical-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard CHOP is a chemotherapy regimen that combines cyclophosphamide, doxorubicin, vincristine, and prednisone to target rapidly dividing cancer cells. Used for Non-Hodgkin lymphoma, Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}